4 ASX stocks smashed today

S&P/ASX 200 Index ends the week with a 1.6% gain

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) has closed the week with a rise of 1.6%, not quite as well as US markets though. Overnight, the Dow Jones, S&P 500 and NASDAQ all posted gains of 1.8%.

It was the second consecutive day of decent gains, but some stocks were still left in the shade. Here's our view on 4 stocks abandoned by investors today.

Altium Limited (ASX: ALU) fell 8.1% to close at $3.07, after the software developer gave an update on the second quarter and half year revenues and sales. Revenues climbed 17% to US$20.3 million for the quarter, with chief financial officer Richard Leon noting that it was in line with expectations. But it seems comments that the company faces some headwinds in the second half was enough to scare off some investors.

Thorn Group Ltd (ASX: TGA) dropped 4.4% to close at $2.84. The company, better known for its Radio Rentals business, has seen its shares climb more than 30% in the past 12 months and appears on track for another good year. In November, Thorn announced a 14% increase in first half profit, as we discussed in this article. At current prices, the company is paying a fully franked dividend yield of around 4% and trading on an undemanding P/E ratio of 14.3x for 2015. It still looks a good buy to me.

Atlas Iron Limited (ASX: ARI) fell 3.6% to 26.5 cents, as did a number of smaller iron ore miners, Arrium Limited (ASX: ARI) and BC Iron Limited (ASX: BCI), which lost 1.7% and 1.4% respectively. That's despite iron ore prices rising 0.6% overnight to US$71.36 per tonne. Perhaps a major factor is that at these prices, no-one really knows if the miners are breaking even, or losing money.

Neuren Pharmaceuticals Ltd (ASX: NEU) lost 8.8% to 15.5 cents, as it continues its topsy-turvy week. Shares in the biotech stock rose more than 10% on Wednesday this week, and despite today's fall, has still posted gains of near 17% for the last five trading days. Volatility is likely to continue, until the company finds out whether the US Food and Drug Administration (FDA) will give approval for Neuren's NNZ-2566 treatment – used to treat a rare condition, Rett Syndrome.

Motley Fool writer/analyst Mike King doesn't own shares in any companies mentioned. You can follow Mike on Twitter @TMFKinga

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »